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Abstract
Meningiomas recur with a rate of 10–32% at ten years. Several features influence the 
risk of recurrence. Our aim is to define the pathological and surgical features at risk of 
diffuse-multicentric versus local-peripheral recurrence. Thirty-three cases of multicen-
tric-diffuse recurrence of intracranial meningiomas were retrospectively analyzed and 
compared with 50 cases who experienced local-peripheral recurrence. The analyzed 
factors included age and sex, tumor location and shape, brain-tumor interface, entity 
of resection, WHO grade, Ki67 MIB1, progesterone receptor (PR) expression, number 
of reoperations, progression of WHO grade, and outcome. The multicentric-diffuse 
recurrences were mainly related to flat-shaped and Ki67 Li greater than 4% features at 
first surgery. Among patients with multicentric-diffuse recurrences, 25 underwent one 
to three reoperations; among them, 17 are alive with local tumor control or slow pro-
gression 2 to 25 years after the initial surgery versus only 2 out of 8 who did not undergo 
surgery. We conclude that flat-shaped meningiomas and those with Ki67 Li greater than 
4% are at higher risk to recur in multicentric-diffuse pattern. Even multiple reopera-
tions over a period of several years may obtain rather long survivals in selected patients 
with prevalent intradural not anaplastic tumors and not too extensive dural infiltration.
Keywords: meningioma recurrence, diffuse recurrence, proliferation index, 
meningioma shape
1. Introduction
The recurrence’s rate of intracranial meningiomas ranges from 10–32% at 
10 years [1–3] .The main risk factors include the WHO grade [4–7], the extent of 
resection according to Simpson [8–10], the proliferation index Ki67-MIB1 [11–14] 
and mitotic index [15] and the postoperative adjuvant treatments [1, 16, 17]. Other 
factors have also been suggested, such as patient age and sex [4, 18], tumor size 
[19–21], location [22, 23] and morphology [19, 22, 24], brain invasion [10, 14], 
progesterone receptor (PR) expression [25–27].
Meningiomas may recur with different patterns of growth, from more localized 
to more extensive and sometimes diffuse forms. This carries several diagnostic 
and therapeutic implications. However, all published studies consider the overall 
Neurosurgery
2
recurrences, with no focusing on their topography and extension, which were first 
discussed only in our recent report [28].
2. Classification of the recurrences
According to their topography on the post-contrast magnetic resonance imaging 
(MRI) and surgical findings, the recurrences of meningiomas may be classified in 4 
types [28]:
• type 1, local, at the previous dural site;
• type 2, peripheral, at the surrounding dura, contiguous to the previous site;
• type 3, multicentric, with multiple nodules both at the dural site and distant, 
with seemly normal interposed dura mater;
• type 4, diffuse, with multiple nodules with interposed dural infiltration, or 
diffuse dural and extradural infiltration.
Local type 1 is the most frequent regrowth pattern. It may occur after resec-
tion of Simpson grades 2 to 4; the tumor may growth both intradurally and at the 
bone. The recurrence may involve from a variable portion to the whole initial dural 
attachment and may extend to the contiguous previously normal dura.
Peripheral type 2 recurrences may be observed after initial resection of grade 
1, but also of grade II when the dural attachment was carefully and extensively 
coagulated. The recurrence may involve a variable dural portion contiguous to the 
initial attachment and may often extend to it. In cases with larger recurrences the 
site of regrowth (local versus peripheral) is difficult to be defined.
Multicentric type 3 recurrences are characterized by tumor nodules or mass both 
at initial dural attachment or contiguous dura and in distal dural regions where 
no tumor nodules nor dural enhancement were visible on the magnetic resonance 
imaging at initial surgery. In this type the dura mater between local-peripheral and 
distal recurrent nodules seems to be normal.
Diffuse type 4 recurrences show multiple nodules of tumor regrowth even in 
very distal regions, with variable infiltration of the interposed dura and bone.
The above discussed patterns of recurrence suggest that multicentric and diffuse 
recurrences are two phases of the same pathological conditions.
3. Pathological origin of the multicentric-diffuse recurrences
The pathological mechanisms responsible for meningioma recurrence in distal 
dural regions are not well defined and deserve to be discussed.
The concept of regional multicentricity of meningiomas is known since about 
35 years. Borovich and Doron [29] demonstrated in convexity meningiomas small 
tumor nodules as well as intradural clusters of tumor cells in the dural specimens 
taken up to 3 cm from the tumor. Qi et al. [30] found tumor invasion in 88% of 
dura adjacent to convexity meningioma up to 2,5 cm from the tumor origin. These 
observations may explain some “unexpected relapses” after an apparent complete 
resection (Simpson grade 1) of convexity meningiomas [29] and the frequent 
peripheral recurrences at the dura surrounding the initial attachment after resec-
tion od Simpson grades 1 and 2 in all locations.
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These pathological findings support the concept of a wide dural excision 2-3 cm 
beyond the tumor base (grade zero resection), which was suggested for convexity 
[31] and falx meningiomas [32].
Mooney et al. [32] suggest that in the falcine meningiomas the tumor cells may 
spread from the site of origin to other falx regions between the two dural leaflets 
of the falx. However, this pattern of diffusion of the tumor cells cannot explain 
the very distant recurrences from other locations. For multiple meningiomas some 
studies [33, 34] have suggested that they may arise from a single progenitor cell and 
could then spread through the subarachnoid space. A similar mechanism may also 
be advocated for distant recurrences.
However, it is more like that multicentric-diffuse recurrences represent the pro-
gressive growth of multiple distant dural nodules with different growth potential. 
In this way the meningioma may be considered, at least in several cases, a diffuse 
disease of the meninges than a localized tumor.
4. Data of the personal series
Thirty-three patients with multicentric-diffuse recurrences of meningiomas are 
included in our series [28] (Tables 1-3 and Figures 1-3). They are 22 females (67%) 
and 11 males (33%), with a median age of 52 years. The findings at initial surgery 
were as follows (Table 1). The most frequent location was non skull-base (55%), 
followed by lateral (36%) and medial skull-base (9%). The tumor was mostly 
flat-shaped (76%) and less frequently round (24%). Complete resection (Simpson 
grades 1 and 2) at initial surgery was obtained in 23 among 33 patients (70%).
The pathological findings at initial diagnosis (Table 1) showed 52% of WHO 
[35] grade I and 48% of grade II tumors; the Ki67-Li was <4% in 20% and ≥ 4%in 
80%. The PR expression was ≤50% in 82% of specimens and > 50% in 9%.
When compared to the findings of meningiomas which showed localized-
peripheral recurrences, only the higher rates of flat-shaped tumors (p = 0.0008) 
and tumors with Ki67-Li ≥4% (p = 0.037) were significant [28].
The management and outcome of the recurrences were as follows (Table 2). 
Twenty-five out of 33 patients (76%) were reoperated on and underwent one (48%) 
or two or three reoperations (52%) (Figures 1 and 2). The complete resection 
(Simpson grades I and II) was possible only in 5 among the 25 patients (20%). The 
histological WHO grade at first reoperation was similar to that of the initial surgery 
in 15 out of 25 patients (60%); progression to a higher grade was observed in 10 
cases (40%).
Adjuvant treatments included external radiotherapy in 20 patients, stereotactic 
radiosurgery in 9 and chemotherapy in 5.
When compared to patients with localized-peripheral recurrences, those 
with multicentric-diffuse recurrences showed significantly higher number of 
reoperations (p = 0.0034), lower rate of gross total resection (p = 0.00001) 
and higher but not significant rate of cases with progression of the WHO grade 
(p = 0.09) [28].
The actual follow-up ranges from 2 to 25 years. One patient died postoperatively for 
respiratory failure. Among the other 24 patients operated on, eleven (34%) are alive 
with local tumor control versus none out of eight patients who did not undergo surgery 
(p = 0.029). Six (25%) show slow tumor progression with no symptoms in spite the sur-
gery. Seven patients of the surgical group (29%) died during the follow-up (5 for tumor 
progression) versus 6 (for tumor progression) out of 8 (75%) of the non-surgical group 
(p = 0.038). Thus, among 25 patients reoperated on 17 (68%) are alive after one or more 
reoperations versus only 2 out of 8 (25%) who did not undergo surgery.
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Covariates Number of cases (rate)
• Surgery 25(76%)
• Number of surgeries
One reoperation 12 (48%)
Two or three reoperations 13 (52%)
• Extent of resection
Gross total 5 (20%)
Subtotal 20 (80%)
• WHO grade at the first reoperation
Similar to the first surgery 15 (60%)
Progression from I to II 7 (28%)
Covariates Number of cases (rate)
Age (mean) 52 y
Sex F 22 (67%)
M 11 (33%)
Tumor location
medial skull base 3 (9%)
lateral skull base 12 (36%)






unclear- lost 18 (55%)









< 4% 7 (20%)
≥ 4% 26 (80%)
P.R. expression





≥ 80% 3 (9%)
Table 1. 
Clinico-radiological, surgical and pathological findings at initial diagnosis (33 patients).
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Statistical significance (Group 1 
Vs Group 2)
Local control 11 (46%) — p = 0.029
Tumor progression 6 (25%) 2 (25%) n.s.
Death during the 
follow-up
7 (29%) 6 (75%) p = 0.038
Table 3. 
Outcome of 33 patients with multicentric-diffuse meningioma recurrence.
Figure 1. 
58 years old woman with history of previous resection of a WHO I grade meningioma of the left frontal 
convexity in 1991. (a) Postoperative CT after the initial surgery: no residual tumor; (b) Post-contrast MRI 
21 years later: local multicentric recurrence at the previous dural site and distal recurrence at the left parietal 
region; (c) Postoperative MRI showing resection of both nodules (WHO grade I) and interposed dura.
Figure 2. 
68 years old man who underwent resection of an anterior parasagittal WHO grade II meningioma in 2010. 
(a-d) Post-contrast MRI, T1 axial (a, d) and coronal (b, c) sequences: diffuse recurrences of the parasagittal 
and both convexity regions with significant tumor masses, at the left parasagittal and convexity and at the 
anterior temporal convexity. Two-stage resection of the masses and irradiation.
Covariates Number of cases (rate)
• Progression from II to III 3 (12%)
• Postoperative death 1 (4%)
• External radiotherapy 20 (60%)
• Stereotactic radiosurgery 9 (27%)
• Chemotherapy 5 (15%)
Table 2. 
Management of 33 patients with multicentric-diffuse recurrences.
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5. Risk factors at initial diagnosis
Several pathological, neuroradiological and surgical findings at initial diagnosis 
are correlated to the meningioma recurrence. However, which factors may be 
considered at risk of multicentric-diffuse recurrence are not defined.
5.1 Location
The meningioma location is a significant risk factor of recurrence. Medial 
skull-base meningiomas include locations, such as olfactory groove, tuberculum 
sellae, anterior clinoid, foramen magnum, with low recurrence rates (0–15%) 
[36–38]. Besides, the low recurrence rate of spinal meningiomas is well known 
(0–10% in 15 among 19 reviewed series in our recent study [39]). On the other 
hand, the reported recurrence rates are higher for lateral skull-base (35–40% for 
lateral sphenoid wing and mainly spheno-orbital [38–40]) and for non-skull base 
meningiomas (16 to 24% for parasagittal and falcine) [23, 41].
However, when the rates of multicentric-diffuse recurrences are considered, the 
differences for intracranial tumor locations are not relevant. Although in our study 
[28] spheno-orbital and parasagittal meningiomas show higher rates of multicentric 
and diffuse recurrences, this finding does not reach significance. Our series does 
not include diffuse recurrences of spinal meningiomas; this agrees with the well 
known better biological behavior of this location.
Thus, the meningioma location is correlated with the rate but not with the 
growth pattern of the recurrences.
5.2 Shape
The shape of meningiomas may be variable. According to the rate height/base on 
magnetic resonance imaging, the meningiomas may be classified as round (rate > 1) 
and flat-shaped (rate ≤ 1). Flat-shaped meningiomas are characterized by prevalent 
and often extensive dural involvement as compared to round-shaped ones. Thus, it 
has been shown that flat-shaped meningiomas are more likely to recur than round 
ones [22, 24].
The flat-shaped morphology at initial diagnosis was the only radiological find-
ing at significantly higher risk of multicentric diffuse recurrence as compared to 
local-peripheral recurrence in our study (p = 0.0008) [28]. Thus, it is like that flat-
shaped meningiomas are associated to various degree of even distant microscopic 
dural infiltration.
Figure 3. 
(a-b) 72 years old man with history of a left spheno-orbital WHO grade II meningioma: a) preoperative T1 
axial post-contrast MRI and (b) postoperative CT scan: complete resection. (c-d) Post-contrast T1 axial  
(c) and coronal (d) MRI sequences seven years after the initial surgery: large tumor recurrence involving the 
left orbital cavity and extending diffusely in the intracranial compartment at the suprasellar, left parasellar 
region and temporal fossa. Management by external radiotherapy.
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5.3 Dural tail
The change of the peritumoral dura mater depicted on the postcontrast mag-
netic resonance studies and defined as “dural tail” is known since its description 
in 1989 [42]. It may correspond to various histopathological patterns, including 
increased loose connective tissue, angiogenesis, dilated vessels, reactive hyperpla-
sia, tumor invasion [42, 43]. Qi et al. [30], in a large series of convexity meningio-
mas, described several types of dural tail with different histological aspects: smooth 
(uniformly extended) with tumor extension up to 1,5 cm; nodular, with nodular 
hyperplasia corresponding to tumor nodules and tumor extension to the distal dura 
up to 2,5 cm; mixed, with nodular enhancement proximal to the dural attachment 
and distal smooth enhancement. In spite of the presence of tumor cells nodules, 
the finding of dural tail was found to be not correlated to the meningioma recur-
rence in most studies [9, 19, 22]. We did not investigate this finding in our series 
of multicentric-diffuse recurrences; however, we suggest that further studies will 
define this aspect.
5.4 Brain-tumor interface
The brain-tumor interface, more often well preserved during meningioma 
surgery, may be unclear or lost, often with variable pial invasion, as in WHO grade 
II tumors. In such cases the tumor resection may be incomplete, with residual nod-
ules mainly in critical regions. This may increase the risk of recurrence at the initial 
site or at the surrounding region [10, 14, 22]. On the other hand, the presence of 
the residual cell nests at the brain-tumor interface does not explain the recurrences 
in distal dural regions and the diffuse regrowths.
5.5 Extent of surgical resection
The entity of the resection at initial surgery is mostly considered a major risk 
factor for recurrence [23, 44, 45]. However, the clinical usefulness of the Simpson 
grading in general has been questioned, at least for benign meningiomas. Some 
studies found no statistically significant differences in progression-free survival 
between Simpson grades 1 to 4[46] and 1 to 3 [13, 47] resections for WHO I grade 
meningiomas. This discrepancy may reflect the technical surgical improvement and 
the smaller tumor remnants in incomplete resections. In a recent report Haddad et 
al. [48]. found that patients with WHO grade I meningiomas and Ki67-MIB1 > 4,5% 
treated by gross total resection had similar risk of recurrence as those patients with 
subtotal resection. In this study, early recurrences were more significantly impacted 
by extent of resection, whereas the Ki67-MIB1 was more significant for later 
recurrences.
In our study on multicentric-diffuse recurrences [28], their rate is not impacted 
by the extent of resection at initial surgery.
5.6 Multiple meningiomas
Multiple meningiomas account for 2 to 8% of all meningiomas [49]. They may 
be diagnosed either initially or during the neuroradiological follow-up.
In a large metanalysis of the literature on multiple meningiomas, Pereira et al. 
[49] found recurrence rate of 8.07% and no higher with respect to single ones. On 
the other hand, in the study by Gousias et al. [45] multiple meningiomas showed 




Multiple meningiomas likely develop from multicentric dural tumor foci accord-
ing to the Borovich [29] theory. A similar mechanism is suggested for multicentric 
recurrences. In our study on multicentric-diffuse recurrences two patients had 
multiple meningiomas (two lesions) at initial diagnosis, with no significant differ-
ences with local-peripheral ones. We think that further studies on the long-term 
follow-up of patients operated on for multiple meningiomas will defined the recur-
rence rates and patterns of these cases.
5.7 Pathological findings
In our study [28] meningiomas with values of Ki67 Li ≥ 4% are related to major 
risk of multicentric-diffuse recurrence, while the WHO grade (I versus II) is not 
significant. Several reports [7, 25–27] confirmed the relationship between higher 
Ki67-Li values and lower PR expression, and higher recurrence risk for intracra-
nial meningiomas. However, in this study the PR expression is not correlated with 
the pattern of diffuse regrowth. Both these findings have not previously been 
reported.
The higher initial values of Ki67 Li of meningiomas recurring as diffuse forms 
suggest that even small dural tumor foci, even distant from the primary tumor site, 
may diffusely regrow.
Several studies have found that different genetic profiles and chromosomal 
abnormalities correspond to different meningioma subtypes with different aggres-
siveness and recurrence’s rate [50–54], making speculate the existence of charac-
teristic biomolecular profiles for meningiomas which recur in multicentric-diffuse 
pattern.
6. Management
The management of multicentric-diffuse recurrences of intracranial meningio-
mas is often difficult to be defined; there are not studies defining the guidelines. 
The management options include a second surgery, external radiotherapy, stereo-
tactic radiosurgery, medical therapy.
The decision is based on several factors, including tumor location (non-skull 
base versus skull base; critical versus not critical), significant intradural mass versus 
prevalent dural infiltration (Figures 4 and 5), entity of bone extension, time to 
recurrence, WHO grade of the initial tumor, patient age and KPS, neurological 
symptoms and signs.
Figure 4. 
Post-contrast MRI of a 58 years old man with history of previous surgery (5 years before) of gross-total resection 
of a bilateral meningioma of the anterior third of the falx (WHO grade II). Sagittal (a-b) and coronal (c-d) 
T1 sequences: distant and diffuse recurrence at the right fronto-temporal bone and suprasellar regions, with 
no recurrence at the initial tumor site. Reoperation and resection of the recurrent tumor (WHO grade II). 
Postoperative death for respiratory failure.
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6.1 Surgery
The indication to reoperation is mainly posed for younger and middle-aged 
patients with symptomatic recurrences. According to the location and pattern of 
regrowth, surgery should be reserved to cases with prevalent intradural tumor 
growth, tumor nodules ≥3 cm and not extensive dural infiltration (Figures 1). Non 
skull-base meningiomas, mainly if limited to the brain convexity, are usually more 
favorable to surgery, because of the chance of more wide resection of the involved 
dura mater. For skull-base meningiomas a more wide resection is possible at the 
anterior cranial fossa and external sphenoid wing; on the other hand, diffuse recur-
rences at the suprasellar, parasellar and spheno-orbital regions (Figure 3), as well 
as clival and petroclival regions, are difficult to treat, because of the involvement of 
the cranial nerves and vessels; for such locations a second surgery is only justified 
for the resection of a large symptomatic intradural mass.
Elderly patients with comorbidities, particularly if with no or trivial neuro-
logical symptoms, must be treated conservatively with periodical radiological 
follow-up.
The WHO grade at initial diagnosis is obviously important. Only WHO grades 
I and II meningiomas are suitable for reoperation. On the other hand, anaplastic 
WHO grade III tumors at initial diagnosis must not be reoperated on.
In selected patients according to the above discussed criteria the reoperation 
results is satisfactory resection of the intradural tumor and involved dura. However, 
a really complete resection with no residual contrast enhancement on MRI 
(Simpson grades 1 and 2) is obtained only in some cases (20% in our series versus 
76% of local-peripheral recurrences) [28].
Further recurrences may be reoperated on following the same criteria, if they 
occur after several years and if the tumor does not progress to anaplastic WHO 
III form.
6.2 Radiotherapy
All studies focusing on the irradiation of recurrent meningiomas include all 
recurrences; thus guidelines of radiotherapy management of diffuse recurrences are 
not available.
The external radiotherapy of multicentric-diffuse recurrences of meningiomas 
is in our opinion mandatory, independently from the entity of resection and the 
WHO grade, but mainly in subtotally or partially resected WHO grade II recur-
rences [55, 56].
Figure 5. 
Post-contrast MRI of a 70 years old woman with history of previous (7 year before) surgical resection  
(Simpson 3) of a WHO grade II meningioma of the posterior parasagittal region: sagittal (a) and coronal 
(b-c) sequences: diffuse recurrence with extensive dural and superior sagittal sinus involvement and tumor 
nodules at the posterior fossa. No reoperation was decided.
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The stereotactic radiosurgery is scarcely indicated, because of the extensive 
and diffuse tumor growth. It may sometimes be performed in association to the 
external radiotherapy to increase the control of smaller nodules and to treat the 
not infrequent second recurrences outside the radiotherapic field [57]. Besides, 
re-radiosurgery for recurrent meningiomas is advisable if the previous radiosurgical 
treatment was unsatisfactory [58].
6.3 Medical therapy
The medical therapy is reserved to recurrent meningiomas which show growth 
progression after surgery and irradiation and to malignant WHO III forms. Many 
clinical trials have studied the effects of cytotoxic chemotherapy [59, 60], hormone-
directed therapy [61, 62], other targeted therapies [63–65] and molecular therapies 
[66]. Targeted and molecular therapies defined on the basis of the biomolecular 
profile of the meningioma may be useful in diffuse-multicentric recurrences show-
ing progression after surgery and radiotherapy.
7. Conclusions
Meningiomas may sometimes recur as multicentric-diffuse forms, with dural 
infiltration and recurrent tumor mass distal to the initial site. These may result from 
the progressive growth of multiple tumor nodules with different growth potential.
Flat-shaped radiological aspect and Ki67 Li ≥4% at initial diagnosis are related 
to higher risk of recurrence in multicentric-diffuse pattern.
Patients with not anaplastic intracranial meningioma with prevalent intradural 
component and not extensive dural infiltration may undergone multiple surgical 
operations during years experimenting good postoperative quality of life.
Further studies will investigate whether the different patterns of regrowth and 
recurrence correspond to different biomolecular and genetic expression of the 
meningioma. This will aid to predict the tumor behavior and to detect the most 
appropriate molecular therapies.
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